Trulieve Cannabis Corp. (TRLV)
AI stock analysis · as of Jun 13, 2026
Loading microstructure…
Trulieve Cannabis is the largest US cannabis retailer by store count (233 locations) with a dominant Florida medical franchise (162 stores) that just became the first US cannabis company to uplist to the NYSE. The core investment question is whether Florida's November 2026 adult-use ballot initiative and/or federal rescheduling to Schedule III will arrive in time to unlock margin and revenue expansion before high-coupon debt (10.5% notes) and 280E taxation continue to compress profitability.
valuationFair-to-slightly-expensive: EV/EBITDA of 7.7x and 10% FCF yield look cheap, but forward P/E of 43x, flat revenue, and -6.9% ROE mean the equity is pricing in a binary FL/rescheduling outcome rather than current fundamentals.
This analysis is from Jun 13, 2026. Want the latest on TRLV, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Strong FCF generation: $212M trailing free cash flow against a ~$2B market cap implies a ~10% FCF yield, unusual for a 'pre-breakeven' growth story
- · Florida adult-use ballot in November 2026 would convert 162 medical stores to adult-use in Trulieve's home-state stronghold — a transformational TAM expansion
- · Federal Schedule III rescheduling would eliminate 280E and could dramatically improve after-tax profitability without any operational change
- · Balance sheet restructuring in Dec 2025 retired $368M of 8% notes and the $15.8M Blue Ridge mortgage, achieving net debt reduction (cash $256M vs debt $564M)
- · EV/EBITDA of 7.7x and P/S of 1.7x are reasonable on an operating basis with 60% gross margins and 12.4% operating margins
- · $50M buyback announcement post-NYSE uplift signals management confidence; NYSE listing opens door to institutional ownership (currently only ~11%)
Bear case
- · Persistent GAAP losses: -$116M net income in 2025 on flat revenue (-0.4% YoY), with revenue actually declining 3.7% on a trailing basis per key_metrics
- · Debt-to-equity of 54.8x is extreme; refinanced into 10.5% coupon notes due 2030, materially raising interest expense vs the retired 8% notes
- · Florida ballot is binary and far away (Nov 2026); the 2024 initiative failed to clear the 60% threshold, and a second failure removes the central catalyst
- · Rohrbacher-Farr rider only extended to Jan 30, 2026 — federal enforcement risk is not theoretical
- · Forward P/E of 43x and P/B of 1.7x with negative ROE (-6.9%) suggest the market already prices in a rescheduling/legalization outcome
- · News flow flags shares down 10.4% post-uplist with GuruFocus calling it overvalued and competitors/hemp eroding pricing in mature markets
Catalysts
- · Florida adult-use ballot initiative vote — November 2026 (requires 60% supermajority)
- · DEA decision on cannabis rescheduling to Schedule III, which would eliminate 280E tax drag
- · Next earnings on August 6, 2026 — watch for margin trajectory and progress toward GAAP breakeven
- · Rohrbacher-Farr appropriations rider renewal/expiration decision around Jan 30, 2026
- · Pennsylvania adult-use legislation introduction in 2026 could unlock 21 additional stores
- · Texas Compassionate Use license finalization opens a new state market
Key risks
- · Florida 2026 adult-use ballot failure — eliminates the central re-rating catalyst
- · Federal rescheduling delay or rejection — 280E continues to crush after-tax profitability
- · Refinancing risk: $200M of 10.5% notes due 2030 at very high coupon if rates stay elevated
- · Price compression from intoxicating hemp and illicit market, particularly in adult-use states
- · Federal enforcement risk if Rohrbacher-Farr lapses post-Jan 2026
- · Revenue is flat-to-declining; if Florida vote fails, there is no organic growth story to fall back on
What to watch
- · Q2 2026 earnings on August 6, 2026 — margin trend and FCF durability
- · Florida adult-use ballot polling through 2026 (needs 60%+ support)
- · DEA/HHS updates on Schedule III rescheduling timeline
- · Execution of $50M buyback — pace and price levels
- · $13.28 52-week high as resistance; $3.25 low and the post-uplist gap as downside reference
- · Rohrbacher-Farr rider status around late January 2026
Key metrics
Price target rationale
Base $12 applies ~9x EV/EBITDA on current run-rate, modestly above the 7.7x current multiple, reflecting NYSE re-rating and optionality. Bull $19 assumes FL ballot passes and/or rescheduling progresses, expanding the multiple toward MSO peers and unlocking 280E relief. Bear $5.5 reflects ballot failure, continued revenue stagnation, and credit concerns around the 10.5% notes — closer to 5-6x EV/EBITDA.
On Wall Street's view (mixed): The $21 consensus target (one analyst, strong buy) implies ~100% upside and likely embeds full credit for both FL adult-use passage and federal rescheduling; we view that as too aggressive given the binary, multi-year nature of both catalysts and the recent post-uplist sell-off.
Latest filing (10-K)
Trulieve is the largest US cannabis retailer with 233 stores and a dominant Florida medical franchise that becomes a transformational growth story if Florida voters legalize adult-use in 2026, but until then the company is squeezed by 280E taxes, high-cost debt, and federal illegality.
Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida. It cultivates, manufactures, and retails cannabis products through 233 dispensaries across nine states (FL, AZ, PA, WV, OH, GA, MD, CT, CO), making it the largest cannabis retailer in the US by store count. Revenue is generated primarily through retail dispensary sales of proprietary and partner-branded cannabis products, with a smaller wholesale component. Florida, with 162 dispensaries, is the dominant market and remains medical-only.
What the news says · neutral
Trulieve's historic uplist to the NYSE as the first U.S. cannabis company on the exchange is the dominant storyline, generating significant media attention and a $50 million buyback announcement that signals management confidence. However, the initial enthusiasm has quickly run into headwinds: shares fell 10.4% shortly after listing, with GuruFocus flagging the stock as still overvalued even after the drop, and analysts at timothysykes.com citing weak momentum and margin concerns. The company is described as 'on the verge of breaking even,' suggesting the fundamental profitability case remains unproven. Overall, the NYSE listing is a meaningful milestone for legitimacy and institutional access, but near-term price action and valuation concerns temper the bullish narrative.
This analysis is from Jun 13, 2026. Markets move. Get the current read on TRLV and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.